Personalized fusion cell vaccines

A method of treating a lymphoma in a subject, the method comprising administering to the subject a T-cell composition, wherein the T-cell composition comprises Chimeric Antigen Receptor T (CAR-T) cells and educated T cells, wherein the educated T cells are obtained by co-culturing T cells with a fusion cell at a ratio of 10:1 T cells to fusion cells for 3 days in the presence of interleukin-2 (IL-2), wherein the fusion cell comprises a fusion of a dendritic cell and a lymphoma cell, and wherein the cells target an antigen expressed by the lymphoma.